Advertisement

 

 

Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs.

Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs.
Author Information (click to view)

Priesner C, Aleksandrova K, Esser R, Mockel-Tenbrinck N, Leise J, Drechsel K, Marburger M, Quaiser A, Goudeva L, Arseniev L, Kaiser A, Glienke W, Koehl U,


Priesner C, Aleksandrova K, Esser R, Mockel-Tenbrinck N, Leise J, Drechsel K, Marburger M, Quaiser A, Goudeva L, Arseniev L, Kaiser A, Glienke W, Koehl U, (click to view)

Priesner C, Aleksandrova K, Esser R, Mockel-Tenbrinck N, Leise J, Drechsel K, Marburger M, Quaiser A, Goudeva L, Arseniev L, Kaiser A, Glienke W, Koehl U,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Human gene therapy 2016 8 25()

Abstract

Multiple clinical studies demonstrated that adaptive immunotherapy using redirected T cells against advanced cancer has led to promising results with improved survival of the patients. The continuously increasing interest in those advanced Gene Therapy Medicinal Products (GTMPs) leads to a challenge on the manufacturing side regarding automation, process robustness and cell storage. Therefore, our study addresses the proof of principle in clinical-scale selection, stimulation, transduction and expansion of T cells using the automated closed CliniMACS® Prodigy system. Naïve and central memory T cells from apheresis products were first immunomagnetically enriched using anti-CD62L magnetic beads and further processed freshly (n=3) or split for cryopreservation and processed after thawing (n=1). Starting with 0.5×108 purified CD3+ T cells, 3 mock runs and one run including transduction with GFP containing vector resulted in a median final cell product of 16×108 T cells (32-fold expansion) up to harvesting after two weeks. Expression of CD62L was downregulated on T cells after thawing which led to the decision to purify CD62L+CD3+ T cells freshly with cryopreservation thereafter. Most important in the split product a very similar expansion curve was reached comparing the overall freshly CD62L selected cells with those after thawing, which could be demonstrated in the T cell subpopulations as well by showing a nearly identical conversion of the CD4/CD8 ratio. In the GFP run the transduction efficacy was 83%. In-process control also demonstrated sufficient glucose levels during automated feeding and medium removal. The process robustness and the constant quality of the final product in a closed and automated system give rise to improve harmonized manufacturing protocols for engineered T cells in future gene therapy studies.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × 4 =

[ HIDE/SHOW ]